Kriya Therapeutics, Inc.’s Post

The article I wrote in collaboration with my colleagues from ttopstart and the AMELIE consortium is now published in Cell & Gene Therapy Insights! Here we discuss how regenerative medicine can be used to treat faecal incontinence.

🚀Check out our new Gene Therapy RESEARCH Portfolio! - #AAV Reference Materials - #LVV Reference Materials - AAV and LVV Plasmids - #ViralVector Packaging Services - Custom Cloning - Molecular Cloning - Gene Synthesis and Mutagenesis - shRNA Cloning #genetherapy #research

Discovering the future of medicine: Germany's cell & gene therapy market 2023-2028 Germany is leading the charge in gene therapies at the forefront of oncological advancements, mainly targeting rare diseases from preclinical stages through pre-registration. 🔗 Want to delve deeper into the trends and data? Check out https://bit.ly/4b4C8Ea #germanycellandgenetherapymarket #cellandgenetherapymarket #focusreportsbyarizton #ariztonresearchreveals #marketresearch #researchreport #marketinsights #markettrends #marketsize #marketshare #marketgrowth #marketforecast #marketexpansion #healthcareandlifesciences

📄 New whitepaper in the Journal of Cell and Gene Therapy Insights highlights the overlooked burden of faecal incontinence (FI) and proposes cell therapy as a transformative solution. The paper discusses the potential of cell therapy to provide a minimally invasive, curative option compared to current treatments. The AMELIE project, supported by CVBF, is a notable initiative in this field. For more details, access the open-access paper. #CellTherapy #MedicalResearch #FaecalIncontinence #AMELIE 

Given the complexity and costs associated with cell and gene therapy trials, you need a clinical research partner who can help you navigate challenges and make sure your trial runs smoothly. Read our white paper to learn more about the importance of strategic alliances for cell & gene therapy trials: https://hubs.la/Q02DTzT-0 #CellandGeneTherapy #CellTherapy #GeneTherapy #ClinicalTrials #ClinicalResearch

❓Fecal incontinence is a condition that is hugely prevalent, yet underreported and stigmatized. 📄 In this article, together with colleagues from ttopstart and the AMELIE project, we hoped to raise awareness and highlight the potential of cell therapy as a potential alternative to the current therapeutic options. 👉🏼To read the full article, you can follow the link in the post below.

In this week’s Sg2 Perspectives, host Jayme Zage, PhD, is joined by Sg2 Associate Principal Justin Cassidy, PhD, to discuss what’s going on in the cell and gene therapy space. Justin talks about the increasing approvals of gene therapies and their primary barriers and challenges, as well as who should be involved in the decisions about receiving these therapies and how providers and manufacturers can gain patients’ trust. https://bit.ly/3ybfRGh

How can the latest cell therapy technologies be harnessed to treat faecal incontinence? Read our newly published article, free to read in the Cell and Gene Therapy Insights journal: https://lnkd.in/ee_aNQYp #faecalincontinence #regenerativemedicine #celltherapy

Are you visiting the Cell and Gene Therapy Pricing and Reimbursement Summit in Washington DC? Hear from Tom Smith on Wednesday June 26, at 11.15am. Tom will be discussing how Uniphar are accelerating global patient access to cell and gene therapies. #CellandGeneTherapy #PricingReimbursement #MarketAccess #ExpandedAccess

Recent advancements have accelerated cell and gene therapy development, leading to more clinical trials and approvals. Discover the transformative tools and techniques from this exciting field detailed in our new eBook. #CellTherapy #GeneTherapy https://lnkd.in/gBUkzSGV